Processes for making cyclic lipid implants for intraocular use

A solid intraocular implant comprising a cyclic lipid therapeutic agent, a polymer and a low melting cosolvent,

• wherein the solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 MPa1/2 of each other;
• wherein the low melting cosolvent has a melt temperature of between about 50° C. and about 80° C.;
• wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, prostaglandin E1, prostaglandin E2, and mixtures thereof;
• wherein the polymer is a biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, and polylactide-co-glycolide;
• and
• wherein the low melting cosolvent is selected from the group consisting of decafluorobutane, poly(hexamethylene adipamide), and polyethylene glycol 3350;
• wherein the cyclic lipid agent comprises 20% by weight of the intraocular implant,
• wherein the potency of the cyclic lipid therapeutic agent released from the implant is at least about 50% of its maximum potency;
• and
• wherein no polymorphs of the therapeutic agent are present in the implant.